MPM BioImpact Portfolio holdings
MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Werewolf Therapeutics
HOWL
|
+$32.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
|
+$13.4M |
| 2 |
Repare Therapeutics
RPTX
|
+$12.9M |
| 3 |
G1 Therapeutics, Inc. Common Stock
GTHX
|
+$2.55M |
| 4 |
iTeos Therapeutics
ITOS
|
+$404K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.25% |
| 2 | Miscellaneous | 4.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Cullinan Oncology
CGEM
$755M
| $204M | 33.48% |
7,913,887
| – | – |
2021 Q1
1 quarter
|
|
|
2
DELISTED
iTeos Therapeutics
ITOS
| $60M | 9.85% |
2,338,581
-16,976
| -0.7% | -$404K |
2020 Q3
3 quarters
|
|
|
TCRR
3
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $55.3M | 9.09% |
3,370,982
| – | – |
2019 Q4
6 quarters
|
|
|
4
DELISTED
Repare Therapeutics
RPTX
| $52.3M | 8.59% |
1,676,087
-393,662
| -19% | -$12.9M |
2020 Q2
4 quarters
|
|
|
HARP
5
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $44.3M | 7.28% |
319,671
-70,171
| -18% | -$13.4M |
2019 Q4
6 quarters
|
|
|
6
Werewolf Therapeutics
HOWL
$47.1M
| $41.6M | 6.84% |
+2,388,011
| New | +$32.7M |
2021 Q2
0 quarters
|
|
|
ONCR
7
DELISTED
Oncorus, Inc.
ONCR
| $32.8M | 5.39% |
2,377,031
| – | – |
2020 Q4
2 quarters
|
|
|
TPTX
8
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $21M | 3.45% |
269,186
| – | – |
2020 Q1
5 quarters
|
|
|
EPZM
9
DELISTED
Epizyme, Inc
EPZM
| $19.4M | 3.18% |
2,331,534
| – | – |
2019 Q4
6 quarters
|
|
|
10
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $17.8M | 2.93% |
812,794
-115,000
| -12% | -$2.55M |
2019 Q4
6 quarters
|
|
11
DELISTED
Merus
MRUS
| $14.8M | 2.43% |
700,879
| – | – |
2020 Q2
4 quarters
|
|
12
DELISTED
Y-mAbs Therapeutics
YMAB
| $11.4M | 1.87% |
337,291
| – | – |
2019 Q4
6 quarters
|
|
13
ADC Therapeutics
ADCT
$213M
| $5.31M | 0.87% |
218,027
| – | – |
2020 Q2
4 quarters
|
|
Similar funds
MPM BioImpact's Q2 2021 Portfolio in Review
As of Q2 2021, MPM BioImpact held 14 positions worth $609M, down 24% from $796M the previous quarter. Its ten largest holdings account for 92% of the portfolio.
MPM BioImpact's Q2 2021 filing shows 1 new and 4 reduced positions. Its largest new stake was Werewolf Therapeutics: 2,388,011 shares worth $41.6M. The largest sale was Harpoon Therapeutics, Inc. Common Stock, an estimated $13.4M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Miscellaneous.
- MPM BioImpact's largest Q2 2021 buy was Werewolf Therapeutics: 2,388,011 shares worth $41.6M.
- MPM BioImpact's biggest Q2 2021 reduction was Harpoon Therapeutics, Inc. Common Stock, cutting an estimated $13.4M.
- MPM BioImpact's ten largest holdings make up 92% of its $609M portfolio in Q2 2021.
- MPM BioImpact opened 1 new position and closed 0 in Q2 2021.
- MPM BioImpact's portfolio value fell 24% quarter-over-quarter to $609M.
Based on MPM BioImpact's 13F filing for Q2 2021, filed 13 Aug 2021.